How can I deliver care not just to the 100,000 patients who might have cancer but to the 500,000 patients who may be at risk of cancer?” That question is shaping the early tenure of Anirban Maitra, MD ...

Researchers created an AI-driven liquid biopsy that scans patterns in fragments of DNA circulating in the blood. The system detected early liver fibrosis and cirrhosis—conditions that often go ...

Pancreatic cancer is the 12th most common cancer worldwide. In 2022, there were 510,992 new cases of pancreatic cancer, with China, the US, and Japan reporting the highest number of cases globally.

The cancer diagnostics industry is evolving rapidly as advances in biotechnology, data analytics and precision medicine continue to reshape how diseases are detected and managed. Within this ...

Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small cell lung cancer will benefit from immunotherapy.

Imagine a screening method that’s more accurate in early detection than a mammogram and less expensive than an MRI. That’s ...

Researchers at the Johns Hopkins Kimmel Cancer Center report that an artificial intelligence (AI)-based liquid biopsy test using genome-wide cell-free DNA (cfDNA) fragmentation patterns and repeat ...

When the performance of AI models was assessed within stratified patient subgroups, such as only high-grade breast cancers or only MSI-positive tumors, accuracy fell substantially, revealing that the ...

University of Warwick research warns that popular deep learning systems trained for cancer pathology may be relying on hidden ...

Artificial intelligence tools are increasingly being developed to predict cancer biology directly from microscope images, ...

New research warns that popular deep learning systems trained for cancer pathology may be relying on hidden shortcuts rather than genuine biological ...

Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for ...